SUDP Gene Panel Sequencing for Cause Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sudden unexpected death in pediatrics (SUDP) remains a leading cause of death in children under 3 years, with current investigation methods often failing to explain the cause of death, particularly in children under 3 years, and there is a need for effective identification of genetic predispositions to SUDP to select appropriate therapies.
Innovation Solution
The development of panels of genes associated with SUDP, utilizing whole exome and genome sequencing to identify sequence alterations, and the use of these panels to select children at risk for targeted therapies by characterizing SUDP genes in biological samples, including those from pediatric probands and their relatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional death scene investigation and autopsy methods are used, then the investigation process is simple and quick, but the ability to identify the cause of death is insufficient
Solution Approach 1:
The investigation process is segmented into conventional autopsy and molecular genetic analysis components. The patent applies segmentation by dividing the diagnostic approach into traditional forensic examination and separate genetic testing of specific genes (SCN1A, SCN2A, SCN3A, KCNQ2, KCNQ3, GABRA1, GABRB3, STXBP1), allowing each component to address specific aspects of cause identification without requiring complete redesign of the entire investigation system.
Solution Approach 2:
Molecular genetic analysis serves as an intermediary between conventional autopsy and cause determination. When conventional methods fail to identify the cause of death, genetic testing of specific candidate genes acts as a mediator to provide additional diagnostic information, bridging the gap between traditional forensic investigation and modern genetic understanding of sudden unexpected death in childhood.
2Measurement precision
If genetic panels are used to identify cause of death, then the precision of cause identification is improved, but the complexity and cost of investigation increases
Solution Approach 1:
Instead of implementing comprehensive whole-genome sequencing for all cases, the patent applies local quality by selecting and testing only specific genes known to be associated with sudden unexpected death in childhood (SCN1A, SCN2A, SCN3A, KCNQ2, KCNQ3, GABRA1, GABRB3, STXBP1). This targeted approach concentrates diagnostic resources on the most relevant genetic targets, improving identification accuracy while limiting complexity to manageable levels.
Solution Approach 2:
The patent implements partial action by performing genetic testing on a selected subset of genes rather than conducting exhaustive genomic analysis. This partial approach focuses on the eight most strongly associated genes, providing sufficient diagnostic precision for many cases without the full complexity and cost of complete genomic sequencing, thereby balancing accuracy with practical constraints.
3Reliability
If comprehensive genetic sequencing is performed on all children, then all genetic factors can be identified, but the time and resources required increase significantly
Solution Approach 1:
The patent applies preliminary action by first performing conventional autopsy and death scene investigation to determine if a cause of death can be identified through traditional methods. Only when these preliminary investigations fail to provide a satisfactory explanation does the protocol proceed to genetic sequencing, thereby avoiding unnecessary genetic testing in cases where conventional methods are sufficient and maintaining investigative efficiency.
Solution Approach 2:
The patent implements partial action by performing genetic testing on a selected subset of genes rather than conducting exhaustive genomic analysis. This partial approach focuses on the eight most strongly associated genes (SCN1A, SCN2A, SCN3A, KCNQ2, KCNQ3, GABRA1, GABRB3, STXBP1), providing sufficient diagnostic precision for many cases without the full complexity and cost of complete genomic sequencing, thereby balancing accuracy with practical constraints.
Data Source
AI summary
The invention features panels of genes associated with Sudden Unexpected Death in Pediatrics (SUDP), and methods of using such panels to identify a cause of death, and to select children at risk of SUDP for therapies to treat pathologies that predispose them to SUDP.